News & Events
Crinetics Announces November 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces November 2022 inducement grants: the stock options were granted as inducements material to four employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
READ MOREEnrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
Enrollment is complete in the placebo-controlled Phase 3 PATHFNDR-1 study evaluating safety and efficacy of once-daily oral paltusotine in acromegaly patients
READ MORECrinetics Announces October 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces October 2022 inducement grants: the stock options were granted as inducements material to 11 employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
READ MOREInnovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism
The UK Medicines and Healthcare products Regulatory Agency has granted CRN04777 an “Innovation Passport” for the treatment of congenital hyperinsulinism.
READ MORECrinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer
Crinetics appoints Dana Pizzuti, M. D. , a 30-year pharmaceutical industry veteran, to the newly created role of chief development officer
READ MORECrinetics Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces September 2022 inducement grants: the stock options were granted as inducements material to 13 employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
READ MORECrinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Crinetics Pharmaceuticals management will present a corporate overview at the H. C. Wainwright 24th Annual Global Investment Conference on September 12, 2022
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
